Simvastatin increases the in vivo activity of the first-line tuberculosis regimen

Ciaran Skerry, Michael L. Pinn, Natalie Bruiners, Richard Pine, Maria L. Gennaro, Petros C. Karakousis

Research output: Contribution to journalArticle

Abstract

Background: The need to develop new, improved treatments for tuberculosis (TB) remains urgent, and the repurposing of existing drugs represents a possible shortcut to market. Recently, there has been significant interest in host-directed adjuvant therapy to enhance bacillary killing. HMG-CoA reductase inhibitors (statins), which are among the most commonly prescribed drugs, have immunomodulatory properties and improve the clinical outcomes of bacterial infections. Methods: We studied the tuberculocidal activity of simvastatin alone and in combination with first-line anti-TB drugs in J774 macrophages and during chronic TB infection. Results: Exposure to 5 μM simvastatin significantly increased the tuberculocidal activity of isoniazid in J774 macrophages at Day 3 after infection versus isoniazid alone (P=0.02). Similarly, relative to the standard oral regimen of rifampicin (10 mg/kg), isoniazid (10 mg/kg) and pyrazinamide (150 mg/kg) given five times weekly, the addition of 25 mg/kg simvastatin enhanced bacillary killing, reducing the number of lung cfu by an additional 1 log10 at Day 28 (P<0.01) and by a further 1.25 log10 at Day 56 (P<0.01). Conclusions: The potential additive activity of simvastatin to first-line TB treatment holds promise. However, further studies to identify the optimal statin and dosing are required. In addition the ability of combination treatment with statins to accelerate the time required to achieve a stable cure remains to be explored.

Original languageEnglish (US)
Article numberdku166
Pages (from-to)2453-2457
Number of pages5
JournalJournal of Antimicrobial Chemotherapy
Volume69
Issue number9
DOIs
StatePublished - Sep 2014

Keywords

  • Lipids
  • Mice
  • Statins
  • TB

ASJC Scopus subject areas

  • Pharmacology
  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Simvastatin increases the in vivo activity of the first-line tuberculosis regimen'. Together they form a unique fingerprint.

  • Cite this